The decision is made off findings from the 2 phase 3, randomized, double-blind, placebo-controlled POETYK PsA-1 and POETYK PsA-2 trials.
he FDA approveddeucravacitinib (Sotyktu; Bristol Myers Squibb) for the treatment of adults with active psoriatic arthritis (PsA), the company announced March 7, 2026.¹ The decision makes deucravacitinib the first oral TYK2 inhibitor approved for PsA — and the first agent in the class to offer rheumatologists a mechanistically differentiated oral option without the boxed warning that accompanies conventional JAK inhibitors.1
For a disease affecting roughly 1/3 of patients with psoriasis and characterized by a heterogeneous mix of joint, skin, entheseal, and axial involvement, the addition of a new oral mechanism is clinically meaningful.4 PsA management has long been complicated by the gap between biologics — effective but injectable, costly, and immunosuppressive — and the available oral agents, where apremilast offers modest efficacy and JAK inhibitors carry a class-wide cardiovascular and malignancy warning that has introduced real prescribing hesitancy, particularly in older patients or those with cardiovascular risk factors.5 Deucravacitinib’s approval does not close that gap entirely, but it adds an option that sits in a different part of the risk-benefit space than anything currently available for this indication.
“Today’s announcement marks the introduction of a new, differentiated option to treat adults with active psoriatic arthritis,” said Al Reba, senior vice president of cardiovascular & immunology commercialization at Bristol Myers Squibb. “This latest approval of Sotyktu confirms its important role in managing both skin and joint symptoms of psoriatic disease and is a key milestone as we continue to explore its development in diseases that have limited or no treatment options.”
The POETYK Trials
The approval is based on 2 phase 3, randomized, double-blind, placebo-controlled trials — POETYK PsA-1 and POETYK PsA-2 — that between them enrolled nearly 1,400 adults with active PsA across biologic-naïve and TNF inhibitor–experienced populations.2,3
In POETYK PsA-1 (NCT04908202; n=670), which enrolled bDMARD-naïve patients, 54.2% of patients receiving deucravacitinib 6 mg once daily achieved ACR20 response at week 16 versus 34.1% on placebo (P <.0001).2 Higher response thresholds followed the same direction: ACR50 was reached by 24.7% versus 13.5%, and ACR70 by 11.6% versus 5.4% at week 16. Skin responses were more pronounced, with PASI 75 achieved in 51.9% of deucravacitinib patients versus 7.1% on placebo (P <.0001). Minimal disease activity was reached by 19.0% versus 10.2% (P <.0001), and improvements in physical function (HAQ-DI), fatigue (FACIT-Fatigue), and quality of life (SF-36 PCS) all reached statistical significance. Notably, the trial also demonstrated inhibition of radiographic progression at week 16 that was maintained through week 52 — a structural endpoint that has historically been difficult to address with oral agents. Patients who crossed over from placebo at week 16 showed reduced radiographic progression by week 52, with outcomes comparable to those on continuous treatment.2
POETYK PsA-2 (NCT04908189; n=729) extended the population to include patients with prior TNF inhibitor exposure and added an apremilast safety reference arm. Results were consistent: 54.2% versus 39.4% on placebo achieved ACR20 at week 16 (P =.0002), with PASI 75 (40.9% vs 15.4%; P <.0001) and minimal disease activity (25.6% vs 14.7%; P =.0007) also significantly favoring deucravacitinib.3 In pooled analyses across both trials, dactylitis resolution was significantly more frequent with deucravacitinib (57.6% vs 44.1%; P =.01), though enthesitis resolution — a clinically important but historically difficult endpoint — was numerically higher without reaching statistical significance (50.3% vs 45.1%).2,3 Responses deepened from week 16 through week 52 and were sustained across both trials.
Safety Profile and the TYK2 Distinction
The safety data are likely to be as influential as the efficacy data in how rheumatologists position this agent. Across both trials through 52 weeks, there were no adjudicated major adverse cardiovascular events, no venous thromboembolism, no opportunistic infections, and no deaths.³˒⁴ Serious adverse events and discontinuations due to adverse events were infrequent and numerically similar to placebo. The most common adverse events — upper respiratory infections (19.2%), elevated creatine phosphokinase (2.7%), herpes simplex (2.0%), mouth ulcers (1.9%), folliculitis (1.7%), and acne (1.4%).
That label distinction matters. Conventional JAK inhibitors — tofacitinib, baricitinib, upadacitinib — inhibit the conserved ATP-binding catalytic domain shared across JAK1, JAK2, and JAK3, producing broad immunomodulatory effects alongside their anti-inflammatory activity. Deucravacitinib works differently: it binds allosterically to the regulatory pseudokinase domain of TYK2, locking the enzyme in an inactive conformation without meaningfully inhibiting the other JAK family members.6 TYK2 is the JAK family member most central to IL-23, IL-12, and type I interferon signaling — the pathways most directly implicated in psoriatic disease — which is why selective inhibition at this node can suppress psoriatic inflammation without the off-target effects that prompted the FDA’s boxed warning for the broader class.
Philip Mease, MD, director of rheumatology research at Providence Swedish Medical Center and a principal investigator on the POETYK program, framed the safety profile in practical terms ahead of the approval in a conversation with RheumatologyLive: “It appears to have a more pristine safety profile, even than some of the JAK1 or JAK3 inhibitors… patients will appreciate having a safe drug that can be used, especially early on, in PsA.”8
However, in a statement, Bristol Myers Squibb noted several warnings and precautions associated with deucravacitinib, including hypersensitivity reactions, infections, tuberculosis, malignancy including lymphomas, rhabdomyolysis and elevated CPK, laboratory abnormalities, immunizations, and potential risks related to JAK inhibition.1
Where It Fits
Deucravacitinib enters a mature treatment landscape where most PsA patients under rheumatologic care are already receiving a biologic or JAK inhibitor, and new agents tend to compete through share shifts rather than expansion of the treated pool. Survey data from Spherix Global Insights published in February 2026 found that about one in three rheumatologists considers deucravacitinib a substantial advance, and most anticipate it displacing other oral therapies — particularly JAK inhibitors and apremilast — rather than established biologic classes.7
That positioning seems feasible, although questions remain with the lack of comparative data. The ACR20 rates in both POETYK trials (54.2% in each) are numerically in the range seen with IL-17 inhibitors in comparable populations, but there are no head-to-head data, and drawing efficacy comparisons across placebo-controlled trials with different populations is unreliable. The enthesitis non-significance in pooled analysis is a gap worth watching in real-world use, as enthesitis is among the most burdensome PsA domains for patients. The structural progression data, while supportive, were modest in magnitude and derived from a 52-week window, so longer term data would add to clinician confidence, and the trial populations were predominantly bDMARD-naïve, leaving the drug’s performance in biologic-experienced patients less well characterized.
None of this undercuts the significance of the approval. For patients with active PsA who are appropriate candidates for oral therapy, whether due to preference, access, or concern about injectable biologics, and in whom JAK inhibitor use is complicated by cardiovascular risk, deucravacitinib now offers a genuinely distinct pharmacological option. Bristol Myers Squibb has also disclosed phase 3 programs in systemic lupus erythematosus and Sjögren’s disease, suggesting the company views TYK2 inhibition as a platform mechanism across autoimmune rheumatology — a bet that, if the PsA clinical profile holds, seems reasonable.1
References
- Bristol Myers Squibb. U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis. March 7, 2026; https://www.businesswire.com/news/home/20260306816774/en/U.S.-FDA-Approves-Bristol-Myers-Squibbs-Sotyktu-deucravacitinib-for-the-Treatment-of-Adults-with-Active-Psoriatic-Arthritis
- Bristol Myers Squibb. Bristol Myers Squibb presents late-breaking data from pivotal phase 3 POETYK PsA-1 trial. Press release. June 11, 2025. https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Presents-Late-Breaking-Data-from-Pivotal-Phase-3-POETYK-PsA-1-Trial-Demonstrating-Superiority-of-Sotyktu-deucravacitinib-Compared-with-Placebo-in-Adults-with-Psoriatic-Arthritis/default.aspx
- Bristol Myers Squibb. Bristol Myers Squibb presents late-breaking data from phase 3 POETYK PsA-2 trial. Press release. March 8, 2025. https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Presents-Late-Breaking-Data-from-Phase-3-POETYK-PsA-2-Trial-Demonstrating-Superiority-of-Sotyktu-deucravacitinib-Compared-with-Placebo-in-Adults-with-Psoriatic-Arthritis/default.aspx
- Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957-970. https://doi.org/10.1056/NEJMra1505557
- Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316-326. https://doi.org/10.1056/NEJMoa2109927
- Wrobleski ST, Moslin R, Lin S, et al. Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165. J Med Chem. 2019;62(20):8973-8995. https://doi.org/10.1021/acs.jmedchem.9b00444
- Spherix Global Insights. One in three rheumatologists view BMS’ Sotyktu as a substantial advance in psoriatic arthritis ahead of March 6 FDA decision. Globe Newswire. February 27, 2026. https://www.globenewswire.com/news-release/2026/02/27/3246703/0/en/One-in-Three-Rheumatologists-View-BMS-Sotyktu-as-a-Substantial-Advance-in-Psoriatic-Arthritis-Ahead-of-March-6-FDA-Decision-According-to-Spherix-Global-Insights-Data.html
- Johnson V. TYK2 inhibitor deucravacitinib up for FDA review for psoriatic arthritis. HCPLive. September 30, 2025. https://www.hcplive.com/view/tyk2-inhibitor-deucravacitinib-up-for-fda-review-for-psoriatic-arthritis